Infectious disease

Clinics in Sports Medicine

Volumn 30, Issue 3, 2011, Pages 575-590

  Jaworski, Carrie A ^a,b   Donohue, Brian ^c   Kluetz, Joshua ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c RESURRECTION MEDICAL CENTER   (United States)

Author keywords

CA MRSA; Infectious disease; Infectious mononucleosis; Influenza; Pertussis; Return to play; Skin infection

Indexed keywords

ACICLOVIR; AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CANTHARIDIN; CEFALEXIN; CIPROFLOXACIN; COTRIMOXAZOLE; DIPHENOXYLATE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ERYTHROMYCIN; FAMCICLOVIR; FLUCONAZOLE; GRISEOFULVIN; IMIQUIMOD; KETOCONAZOLE; LOPERAMIDE; MACROLIDE; METRONIDAZOLE; OSELTAMIVIR; PENICILLIN G; PSEUDOMONIC ACID; QUINOLONE DERIVATIVE; RIFAXIMIN; STEROID; TERBINAFINE; UNINDEXED DRUG; VALACICLOVIR; WART VIRUS VACCINE; ZANAMIVIR;

AMINOTRANSFERASE BLOOD LEVEL; ATHLETE; ATHLETIC PERFORMANCE; BRONCHITIS; CRYOTHERAPY; CURETTAGE; DRUG EFFICACY; DRUG INDUCED HEADACHE; EPSTEIN BARR VIRUS; ESCHERICHIA COLI; FLUID THERAPY; FOLLICULITIS; HEPATITIS B; HERPES GLADIATORUM; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTROPHY; IMMUNE RESPONSE; IMPETIGO; INFECTION; INFECTION CONTROL; INFECTION RISK; INFECTIOUS MONONUCLEOSIS; INFLUENZA; INFLUENZA A; INFLUENZA B; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOLLUSCUM CONTAGIOSUM; OUTCOME ASSESSMENT; PARESTHESIA; PERTUSSIS; PHARYNGITIS; PHOTOSENSITIVITY; RASH; REVIEW; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN INFECTION; SPLEEN RUPTURE; STAPHYLOCOCCUS; STREPTOCOCCAL PHARYNGITIS; STREPTOCOCCUS; TINEA; TRAVELLER DIARRHEA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ATHLETES; BRONCHITIS; COMMUNICABLE DISEASES; GASTROINTESTINAL TRACT; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS MONONUCLEOSIS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; SEXUALLY TRANSMITTED DISEASES; SKIN; STAPHYLOCOCCAL SKIN INFECTIONS; WHOOPING COUGH;

EID: 79958102359     PISSN: 02785919     EISSN: 1556228X     Source Type: Journal    
DOI: 10.1016/j.csm.2011.03.006     Document Type: Review

References (74)

1. Gleeson M. Immune function in sport and exercise. J Appl Physiol 2007, 103:693-699.
2. Nieman D.C. Exercise, infection and immunity. Int J Sports Med 1994, 15:S131-S141.
3. Beneson A.S. Acute viral respiratory diseases in control of communicable diseases in man 1975, American Public Health Association, Washington, DC, p. 262-6.
4. Orhant E., Carling C., Cox A. A three-year prospective study of illness in professional soccer players. Res Sports Med 2010, 18(3):199-204.
5. Mountjoy M., Junge A., Alonso J.M., et al. Sports injuries and illnesses in the 2009 FINA World Championships (Aquatics). Br J Sports Med 2010, 44(7):522-527.
6. Castellani J.W., Brenner I.K., Rhind S.G. Cold exposure: human immune responses and intracellular cytokine expression. Med Sci Sports Exerc 2002, 34:2013-2020.
7. WADA Prohibited List Available at:, Accessed January 3, 2011. http://www.wada-ama.org/en/World-Anti-Doping-Program/Sports-and-Anti-Doping-Organizations/International-Standards/Prohibited-List/.
8. Metz J.P. Upper respiratory tract infections: who plays, who sits?. Curr Sports Med Rep 2003, 2:84-90.
9. Eichner E.R. Infection, immunity, and exercise: what to tell your patients. Phys Sportsmed 1993, 21:125.
10. Luzuriaga K., Sullivan J.L. Infectious mononucleosis. N Engl J Med 2010, 362:1993-1999.
11. Crawford D.H., Macsween K.F., Higgins C.D., et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 2006, 43:276-282.
12. Ebell M.H. Epstein-Barr virus infectious mononucleosis. Am Fam Physician 2004, 70:1279-1287.
13. Vidrih J.A., Walensky R.P., Sax P.E., et al. Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am J Med 2001, 111:192-194.
14. Kinderknecht J.J. Infectious mononucleosis and the spleen. Curr Sports Med Rep 2002, 1:116-120.
15. Bennett N.J., Domachowske J. Mononucleosis and Epstein-Barr virus infection Available at:, Accessed January 4, 2011. http://emedicine.medscape.com/article/963894-overview.
16. Candy B., Hotopf M. Steroids for symptom control in infectious mononucleosis. Cochrane Database Syst Rev 2006, 3. CD004402.
17. Farley D.R., Zietlow S.P., Bannon M.P., et al. Spontaneous rupture of the spleen due to infectious mononucleosis. Mayo Clin Proc 1992, 67:846-853.
18. Hosey R.G., Mattacola C.G., Kriss V., et al. Ultrasound assessment of spleen size in collegiate athletes. Br J Sports Med 2006, 40:251-254.
19. McCorkle R., Thomas B., Suffaletto H., et al. Normative spleen size in tall healthy athletes: Implications for safe return to contact sports after infectious mononucleosis. Clin J Sport Med 2010, 20:413-415.
20. Hosey R.G., Kriss V., Uhl T.L., et al. Ultrasonographic evaluation of splenic enlargement in athletes with acute infectious mononucleosis. Br J Sports Med 2008, 42:974-977.
21. Putukian M., O'Connor F.G., Stricker P., et al. Mononucleosis and athletic participation: an evidence-based subject review. Clin J Sport Med 2008, 18:309-315.
22. Waninger K.N., Harcke H.T. Determination of safe return to play for athletes recovering from infectious mononucleosis. Clin J Sport Med 2005, 15:410-416.
23. Hosey R.G., Rodenberg R.E. Infectious disease and the collegiate athlete. Clin Sports Med 2007, 26:449-471.
24. Braman S.S. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006, 129(Suppl 1):955-1035.
25. Petersen I., Johnson A.M., Islam A., et al. Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database. BMJ 2007, 335:982.
26. Edwards K.M. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J 2005, 24:S104-S108.
27. Kr Broder, Cortese M.M., Iskander J.K., et al. Advisory Committee on Immunization Practices. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55:1-34.
28. Kretsinger K., Kr Broder, Cortese M.M., et al. Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices: Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the ACIP. MMWR Recomm Rep 2006, 55:1-37.
29. Centers for Disease Control and Prevention Pertussis: summary of vaccine recommendations Available at:, Accessed January 4, 2011. http://www.cdc.gov/vaccines/vpd-vac/pertussis/recs-summary.htm.
30. Cornia P.B., Hersh A.L., Lipshy B.A., et al. Does this coughing adolescent or adult patient have pertussis?. JAMA 2010, 304:890-896.
31. Centers for Disease Control and Prevention Guidelines for pertussis Available at:, Accessed December 14, 2010. http://www.cdc.gov/vaccines/pubs/pertussis-guide/downloads/chapter8.pdf.
32. Centers for Disease Control and Prevention Updated CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States, April 2009-April 10, 2010 Available at:, Accessed December 14, 2010. http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm.
33. Dawood F.S., Jain S., Finelli L., et al. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360:2605-2615.
34. Treanor J.J., Hayden F.G., Vrooman P.S., et al. US Oral Neuraminidase Study Group. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000, 283:1016-1024.
35. Jefferson T., Jones M., Doshi P., et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systemic review and meta-analysis. BMJ 2009, 339:b5106.
36. Harper S.A., Bradley J.S., Englund J.A., et al. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1003-1032.
37. Advisory Committee on Immunization Practices ACIP provisional recommendations for the use of influenza vaccines Available at:, Accessed December 14, 2010. http://www.cdc.gov/flu/professionals/acip/flu_vax1011.htm.
38. Hill D.R. Occurrence and self-treatment of diarrhea in a large cohort of Americans traveling to developing countries. Am J Trop Med Hyg 2000, 62:585-589.
39. DuPont H.L., Ericsson C.D. Prevention and treatment of travelers' diarrhea. N Engl J Med 1990, 328:1821-1827.
40. DeLee J.C., Drez D., Miller M.D. DeLee and Drez's Orthopaedic Sports Medicine 2009, WB Saunders, Philadelphia, Chapter 3. 3rd edition.
41. Goodgame R. Emerging causes of traveler's diarrhea: Cryptosporidium, Cyclospora, Isospora, and Microsporidia. Curr Infect Dis Rep 2003, 5:66-73.
42. Adachi J.A., Ericsson C.D., Jiang Z.D., et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003, 37:1165-1171.
43. Adachi J.A., DuPont H.L. Rifaximin: a novel nonabsorbed refamycin for gastrointestinal disorders. Clin Infect Dis 2006, 42:541-547.
44. Murphy G.S., Bodhidatta L., Echeverria P., et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med 1993, 118:582-586.
45. Dielubanza E.J., Schaeffer A.J. Urinary tract infections in women. Med Clin North Am 2011, 95:27-41.
46. Zhanel G.G., Hisanaga T.L., Laing N.M., et al. Antibiotic resistance in outpatient urinary isolates: final results from the North American urinary tract infection collaborative alliance (NAUTICA). Int J Antimicrob Agents 2006, 27:468-475.
47. Wagenlehner F.M., Weidner W., Naber K.G. An update on uncomplicated urinary tract infections in women. Curr Opin Urol 2009, 19:268-274.
48. Milo G., Katchman E., Paul M., et al. Duration of antibacterial treatment for uncomplicated urinary tract infections in women. Cochrane Database Syst Rev 2005, 2. CD004682.
49. Raynor M.C., Carson C.C. Urinary infections in men. Med Clin North Am 2011, 95:43-54.
50. Barbosa-Cesnik C., Brown M.B., Buxton M., et al. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clin Infect Dis 2011, 52:23-30.
51. Centers for Disease Control and Prevention Trends in sexually transmitted diseases in the United States: 2009 national data for gonorrhea, chlamydia and syphilis Available at:, Accessed December 14, 2010. http://www.cdc.gov/std/stats09/trends.htm.
52. Pope H.G., Katz D.L., Champoux R. Anabolic-androgenic steroid use among 1,010 college men. Phys Sportsmed 1988, 16:75-84.
53. NCAA 2010-11 Sports Medicine Handbook. Guideline 21-Blood-borne Pathogens and Intercollegiate Athletics. Indianapolis (IN): NCAA; p. 66-71.
54. American Academy of Pediatrics Committee on Infectious Deisease Hepatitis C virus infection 1998, American Academy of Pediatrics, Elk Grove Village (IL).
55. Gutierrez R.L., Decker C.F. Blood-borne infections and the athlete. Dis Mon 2010, 56:436-442.
56. American Medical Society for Sports Medicine and the American Orthopedic Society for Sports Medicine: human immunodeficiency virus and other blood borne pathogens in sports Joint position statement. Am J Sports Med 1995, 23(4):510-514.
57. Zinder S.M., Basler R., Foley J., et al. National athletic trainers' association position statement: skin diseases. J Athl Train 2010, 45(4):411-428.
58. Sports related skin infections: position statement and guidelines. National Federation of State High School Associations. Available at: Accessed December 12, 2010. http://www.nfhs.org.
59. Cutaneous fungal infections. Color atlas and synopsis of clinical dermatology 1997, 688-733. McGraw-Hill, New York. 3rd edition. T.B. Fitzpatrick, R.A. Johnson, K. Wolff (Eds.).
60. Gupta A.K., Cooper E.A., Ryder J.E., et al. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol 2004, 5:225-237.
61. Brickman K., Einstein E., Sinha S., et al. Fluconazole as a prophylactic measure for tinea gladiatorum in high school wrestlers. Clin J Sport Med 2009, 19:412-414.
62. Anderson B.J. The epidemiology and clinical analysis of several outbreaks of herpes gladiatorum. Med Sci Sports Exerc 2003, 11:1809-1814.
63. Barton S.E., Ebel C.W., Kirchner J.T., et al. The clinical management of recurrent genital herpes: current issues and future prospects. Herpes 2002, 9:15-20.
64. Anderson B.J. Managing herpes gladiatorum outbreaks in competitive wrestling: the 2007 Minnesota experience. Curr Sports Med Rep 2008, 7(6):323-327.
65. Theos A.U., Cummins R., Silverberg N.B., et al. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double blind, randomized pilot trial. Cutis 2004, 74:134-142.
66. Syed T.A., Lundin S., Ahmad M. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of molluscum contagiosum in males. A placebo-controlled, double-blind study. Dermatology 1994, 189(1):65-68.
67. Habif T. Clinical dermatology 2009, Elsevier Health Sciences, Philadelphia, Chapter 9. 5th edition.
68. Kazakova S.V., Hageman J.C., Matava M., et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005, 352(5):468-475.
69. Creech C.B., Saye E., McKenna B.D., et al. One-year surveillance of methicillin-resistant Staphylococcus aureus nasal colonization and skin and soft tissue infections in collegiate athletes. Arch Pediatr Adolesc Med 2010, 164(7):615-620.
70. Moellering R.C. Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008, 46:1032-1037.
71. Gowitz R.J. The role of ancillary antimicrobial therapy for the treatment of uncomplicated skin infections in the era of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007, 44:785-787.
72. Harbarth S., Dharan S., Liassine N., et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrobial Agents Chemother 1999, 43(6):1412-1416.
73. Garza D., Sungar G., Johnston T., et al. Ineffectiveness of surveillance to control community-acquired methicillin-resistant Staphylococcus aureus in a professional football team. Clin J Sport Med 2009, 19(6):498-501.
74. Elston D.M. How to handle a CA-MRSA outbreak. Dermatol Clin 2009, 27:43-48.